Hepatic Resection for Gastrointestinal Stromal Tumor Liver Metastases

Hematology/Oncology Clinics of North America

Volumn 23, Issue 1, 2009, Pages 115-127

  Zalinski, Stephane ^a   Palavecino, Martin ^a   Abdalla, Eddie K ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Extended hepatectomy; Gastrointestinal stromal tumor; Imatinib; Liver metastasis; Liver resection; Liver volumetry; Portal vein embolization; Tyrosine kinase inhibitor

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR;

CANCER SURVIVAL; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HUMAN; LIVER METASTASIS; LIVER RESECTION; PRIORITY JOURNAL; REVIEW; TUMOR RECURRENCE;

COMBINED MODALITY THERAPY; GASTROINTESTINAL STROMAL TUMORS; HUMANS; LIVER NEOPLASMS; PROTEIN KINASE INHIBITORS;

EID: 60549101679     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2008.11.001     Document Type: Review

References (59)

1. Joensuu H. Gastrointestinal stromal tumor (GIST). Ann Oncol 17 Suppl 10 (2006) x280-x286
2. Joensuu H., Roberts P.J., Sarlomo-Rikala M., et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344 14 (2001) 1052-1056
3. van Oosterom A.T., Judson I., Verweij J., et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358 9291 (2001) 1421-1423
4. Scaife C.L., Hunt K.K., Patel S.R., et al. Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate?. Am J Surg 186 6 (2003) 665-669
5. Antonescu C.R., Besmer P., Guo T., et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 11 11 (2005) 4182-4190
6. Chen L.L., Trent J.C., Wu E.F., et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 64 17 (2004) 5913-5919
7. Heinrich M.C., Corless C.L., Demetri G.D., et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21 23 (2003) 4342-4349
8. Crosby J.A., Catton C.N., Davis A., et al. Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol 8 1 (2001) 50-59
9. DeMatteo R.P., Shah A., Fong Y., et al. Results of hepatic resection for sarcoma metastatic to liver. Ann Surg 234 4 (2001) 540-547 [discussion 547-8]
10. Pierie J.P., Choudry U., Muzikansky A., et al. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg 136 4 (2001) 383-389
11. Katz S.C., and DeMatteo R.P. Gastrointestinal stromal tumors and leiomyosarcomas. J Surg Oncol 97 4 (2008) 350-359
12. DeMatteo R.P., Lewis J.J., Leung D., et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231 1 (2000) 51-58
13. Adam R., Chiche L., Aloia T., et al. Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model. Ann Surg 244 4 (2006) 524-535
14. Elias D., Cavalcanti de Albuquerque A., Eggenspieler P., et al. Resection of liver metastases from a noncolorectal primary: indications and results based on 147 monocentric patients. J Am Coll Surg 187 5 (1998) 487-493
15. Hemming A.W., Sielaff T.D., Gallinger S., et al. Hepatic resection of noncolorectal nonneuroendocrine metastases. Liver Transpl 6 1 (2000) 97-101
16. Pawlik T.M., Vauthey J.N., Abdalla E.K., et al. Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver. Arch Surg 141 6 (2006) 537-543 [discussion 543-4]
17. Schwartz S.I. Hepatic resection for noncolorectal nonneuroendocrine metastases. World J Surg 19 1 (1995) 72-75
18. Nunobe S., Sano T., Shimada K., et al. Surgery including liver resection for metastatic gastrointestinal stromal tumors or gastrointestinal leiomyosarcomas. Jpn J Clin Oncol 35 6 (2005) 338-341
19. Perez E.A., Gutierrez J.C., Jin X., et al. Surgical outcomes of gastrointestinal sarcoma including gastrointestinal stromal tumors: a population-based examination. J Gastrointest Surg 11 1 (2007) 114-125
20. Perez E.A., Livingstone A.S., Franceschi D., et al. Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors. J Am Coll Surg 202 4 (2006) 623-629
21. Haller F., Detken S., Schulten H.J., et al. Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations. Ann Surg Oncol 14 2 (2007) 526-532
22. Gold J.S., and Dematteo R.P. Neoadjuvant therapy for gastrointestinal stromal tumor (GIST): racing against resistance. Ann Surg Oncol 14 4 (2007) 1247-1248
23. DeMatteo R.P. Treatment of advanced gastrointestinal stromal tumor: a marriage of targeted therapy and surgery?. Ann Surg Oncol 14 1 (2007) 1-2
24. Verweij J., Casali P.G., Zalcberg J., et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364 9440 (2004) 1127-1134
25. Pantaleo M.A., Di Battista M., Catena F., et al. Surgical debulking of gastrointestinal stromal tumors: is it a reasonable option after second-line treatment with sunitinib?. J Cancer Res Clin Oncol 134 5 (2008) 625-630
26. Farges O., Belghiti J., Kianmanesh R., et al. Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg 237 2 (2003) 208-217
27. Nagino M., Kamiya J., Nishio H., et al. Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer: surgical outcome and long-term follow-up. Ann Surg 243 3 (2006) 364-372
28. Shoup M., Gonen M., D'Angelica M., et al. Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. J Gastrointest Surg 7 3 (2003) 325-330
29. Abdalla E.K., Adam R., Bilchik A.J., et al. Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 13 10 (2006) 1271-1280
30. Abdalla E.K., Barnett C.C., Doherty D., et al. Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg 137 6 (2002) 675-680 [discussion 680-1]
31. Vauthey J.N., Pawlik T.M., Abdalla E.K., et al. Is extended hepatectomy for hepatobiliary malignancy justified?. Ann Surg 239 5 (2004) 722-730 [discussion 730-2]
32. Vauthey J.N., Palavecino M., Curley S.A., et al. Re: right hepatic trisectionectomy for hepatobiliary disease: results and an appraisal of its current role. Ann Surg 248 1 (2008) 138-139 [author reply 139-40]
33. Madoff D.C., Hicks M.E., Vauthey J.N., et al. Transhepatic portal vein embolization: anatomy, indications, and technical considerations. Radiographics 22 5 (2002) 1063-1076
34. Ribero D., Abdalla E.K., Madoff D.C., et al. Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome. Br J Surg 94 11 (2007) 1386-1394
35. Chun Y.S., and Vauthey J.N. Extending the frontiers of resectability in advanced colorectal cancer. Eur J Surg Oncol 33 Suppl 2 (2007) S52-S58
36. Chun Y.S., Ribero D., Abdalla E.K., et al. Comparison of two methods of future liver remnant volume measurement. J Gastrointest Surg 12 1 (2008) 123-128
37. Miller A.B., Hoogstraten B., Staquet M., et al. Reporting results of cancer treatment. Cancer 47 1 (1981) 207-214
38. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 3 (2000) 205-216
39. Choi H., Charnsangavej C., Faria S.C., et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25 13 (2007) 1753-1759
40. Van den Abbeele A.D., and Badawi R.D. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer 38 Suppl 5 (2002) S60-S65
41. Dematteo R.P., Gold J.S., Saran L., et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 112 3 (2008) 608-615
42. Martin J., Poveda A., Llombart-Bosch A., et al. Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). J Clin Oncol 23 25 (2005) 6190-6198
43. Hassan I., You Y.N., Shyyan R., et al. Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis. Ann Surg Oncol 15 1 (2008) 52-59
44. Heinrich M.C., Corless C.L., Blanke C.D., et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24 29 (2006) 4764-4774
45. Debiec-Rychter M., Dumez H., Judson I., et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 40 5 (2004) 689-695
46. Debiec-Rychter M., Sciot R., Le Cesne A., et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42 8 (2006) 1093-1103
47. Bucher P., Villiger P., Egger J.F., et al. Management of gastrointestinal stromal tumors: from diagnosis to treatment. Swiss Med Wkly 134 11-12 (2004) 145-153
48. Dematteo R.P., Heinrich M.C., El-Rifai W.M., et al. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 33 5 (2002) 466-477
49. Rossi C.R., Mocellin S., Mencarelli R., et al. Gastrointestinal stromal tumors: from a surgical to a molecular approach. Int J Cancer 107 2 (2003) 171-176
50. Maluccio M.A., Covey A.M., Schubert J., et al. Treatment of metastatic sarcoma to the liver with bland embolization. Cancer 107 7 (2006) 1617-1623
51. Clary B.M., DeMatteo R.P., Lewis J.J., et al. Gastrointestinal stromal tumors and leiomyosarcoma of the abdomen and retroperitoneum: a clinical comparison. Ann Surg Oncol 8 4 (2001) 290-299
52. Bonvalot S., Eldweny H., Pechoux C.L., et al. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Ann Surg Oncol 13 12 (2006) 1596-1603
53. DeMatteo R.P., Maki R.G., Singer S., et al. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 245 3 (2007) 347-352
54. Gronchi A., Fiore M., Miselli F., et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg 245 3 (2007) 341-346
55. Raut C.P., Posner M., Desai J., et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 24 15 (2006) 2325-2331
56. Demetri G.D., von Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347 7 (2002) 472-480
57. Adam R., Delvart V., Pascal G., et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240 4 (2004) 644-657
58. Verweij J., van Oosterom A., Blay J.Y., et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 39 14 (2003) 2006-2011
59. Gutierrez J.C., De Oliveira L.O., Perez E.A., et al. Optimizing diagnosis, staging, and management of gastrointestinal stromal tumors. J Am Coll Surg 205 3 (2007) 479-491 [quiz 524]